Rationale: Up to one-third of patients hospitalized with pneumococcal pneumonia experience major adverse cardiac events (MACE) during or after pneumonia. In mice, Streptococcus pneumoniae can invade the myocardium, induce cardiomyocyte death, and disrupt cardiac function following bacteremia, but it is unknown whether the same occurs in humans with severe pneumonia.
Lower respiratory tract infections cost the healthcare system more than $10 billion annually in the United States (1, 2) . Community-acquired pneumonia (CAP) and influenza infections together represent the fourth most prevalent cause of death worldwide (3) . The morbidity, mortality, and costs associated with CAP have remained unchanged in recent decades, despite the availability of antibiotic treatments and preventive strategies with immunizations (4, 5) . Approximately 30% of patients hospitalized with CAP experience major adverse cardiac events (MACE) during hospitalization and up to 10 years after infection (6) (7) (8) (9) . Importantly, patients with pneumonia and MACE have double the hospital mortality compared with those with pneumonia alone (6, 10) . MACE in patients with CAP include new-onset or worsening heart failure, arrhythmias, stroke, and acute coronary syndrome (9) . Risk factors for MACE during CAP include infection with Streptococcus pneumoniae, older age, severe CAP, hyperlipidemia, obesity, and arterial hypertension (6, 8, 11, 12) . The pathophysiology of MACE during CAP has been attributed to the complex host-pathogen interactions, but the exact mechanisms are not well understood (9, 13) .
S. pneumoniae (pneumococcus) is the most frequent bacterial pathogen in patients with CAP (14, 15) . Pneumococcal pneumonia has been identified as an independent risk factor for the development of MACE during CAP (6, 8, 11, 12, 16) . Pneumococcal pneumonia can result in cardiovascular complications in 10 to 30% of patients, affecting mainly those with existing cardiovascular diseases (11, 12) . Recently, our research group (17, 18) and other researchers (19) (20) (21) have described that the pneumococcus and its virulence factors (e.g., pneumolysin, bacterial cell wall) have direct detrimental effects on the cardiac function of rodents with invasive pneumococcal disease (IPD). We have demonstrated that pneumococcus can invade the heart and cause small, bacteria-filled lesions within the myocardium (17, 18) . These myocardial lesions disrupt cardiac contractility, induce cardiomyocyte death, and subsequently cause de novo collagen deposition in mice rescued with antibiotics (convalescent mice) (17, 22) . Moreover, we have shown that S. pneumoniae is capable of inducing necroptosis, a highly proinflammatory programmed cell death pathway, in lung macrophages during pneumonia (23) . Pertinent to the present study, necroptosis has been recognized as a key cell death pathway in cardiomyocytes during ischemiareperfusion injury and acute coronary syndrome (24) (25) (26) .
Despite epidemiological studies demonstrating that pneumococcal infection is an independent risk factor for MACE (6-8, 11, 12) , it is unknown whether S. pneumoniae can generate direct cardiac cytotoxicity (e.g., cell death), heart failure, clinically relevant arrhythmias, or acute coronary syndrome (i.e., MACE) in humans with severe pneumococcal pneumonia (11, 12, 16, 27) . Additionally, the potential underlying mechanisms of MACE during pneumococcal pneumonia have been described in rodent models, but it is speculative to extrapolate these findings to humans. To address this knowledge gap, we used a validated nonhuman primate (NHP) model of severe pneumococcal pneumonia that closely mimics human disease (28) to explore the mechanisms of pneumococcal cytotoxicity on cardiomyocytes. Potential translation of these findings to humans includes identification of potential therapeutic targets to prevent MACE and, ultimately, improvement in clinical outcomes of patients with CAP.
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At a Glance Commentary
Scientific Knowledge on the Subject: Streptococcus pneumoniae is the most frequently isolated bacterial pathogen in patients with communityacquired pneumonia (CAP). As a result of highly complex host-pathogen interactions, patients with pneumococcal pneumonia are at increased risk of developing cardiovascular complications during and after CAP, including heart failure, arrhythmias, stroke, and acute coronary syndrome. Recent studies in mice revealed that S. pneumoniae is capable of invading the heart and causing direct cardiac damage during invasive pneumococcal disease. Yet, murine pneumococcal pneumonia is poorly representative of human disease, and whether cardiac invasion occurs during severe pneumonia in humans is unknown. Our aim in this study was to determine, using a validated nonhuman primate model that closely resembles pneumococcal disease in humans, if pneumococcus (1) invades the myocardium, (2) induces cardiomyocyte death, and (3) elicits cardiovascular complications during pneumococcal pneumonia.
What This Study Adds to the
Field: This study presents novel evidence that S. pneumoniae can invade the heart during severe pneumonia and induce cardiomyocyte death via direct cytotoxic effects. These findings could potentially explain the development of short-and long-term cardiac complications associated with CAP due to acute cardiomyocyte injury and induction of scar formation in the hearts of convalescent nonhuman primates.
Methods
These animal studies were performed at the Texas Biomedical Research Institute in San Antonio, Texas. This animal protocol along with all animal experiments were reviewed and approved by the institutional animal care and use committee (IACUC number 1443PC6) at the Texas Biomedical Research Institute.
Study Design
A full description of the NHP model of severe pneumococcal pneumonia has been published previously (28) . Briefly, six healthy adult baboons (Papio cynocephalus), including four males, were bronchoscopically challenged with 10 9 colony-forming units of S. pneumoniae serotype 4 (strain TIGR4 [29] ). Collection of blood for serum biomarkers and bacterial load estimation, acquisition of a 12-lead ECG and a transthoracic echocardiogram, and bronchoalveolar lavage were performed before the infection and at the end of the experiment before animals were killed (28) . Continuous 24-hour temperature, heart rate, and three-lead ECG were recorded throughout the experiment via a surgically implanted tether. At the end of the experiment, the hearts were harvested and prepared for tissue experiments. Three NHPs were treated with intravenous ampicillin (80 mg/kg/d) for 7 days (the convalescent group) (28) . All ECGs were read by an expert electrophysiologist (A.J.) who was blinded to the experiment results. The study design is summarized in Figure E1 in the online supplement. Finally, MACE were defined as heart failure, arrhythmias, or myocardial infarctions.
Study Groups
The cohort was divided in two groups to mimic the preantibiotic era and modern era of patients with pneumonia (28) . For the preantibiotic era group, we did not treat three NHPs with antibiotics, and they were called the acute pneumonia group and killed per protocol 4-6 days after infection. In the modern era of pneumonia group, three NHPs were rescued with antibiotic treatment, and they were called the convalescent pneumonia group and killed per protocol 9-14 days after infection (28) . The end of the experiment refers to the moment before animals were killed, which varied for each animal according to the study groups just described (28) . Heart tissues of three age-and sex-matched uninfected NHPs served as controls ( Figure E1 ).
Transthoracic Echocardiogram Evaluation
A standard five-view focused cardiac ultrasound examination was performed using a portable ultrasound machine (GE LOGIQ e Vet; GE Healthcare, Little Chalfont, UK) equipped with microconvex (GE model 8C-RS, 4.0-10.0 MHz; GE Healthcare) and phased-array (GE model 3S-RS, 1.7-4.0 MHz; GE Healthcare) transducers. Parasternal long-and short-axis, apical and subcostal four-chamber, and subcostal inferior vena cava (IVC) views were obtained to assess the left ventricular (LV) and right ventricular size and function, cardiac valves, pericardium, and IVC size and collapsibility.
Serum Cardiac Biomarkers
Serum levels of ultrasensitive troponin T (Life Diagnostics, West Chester, PA), heart-type fatty acid binding protein (H-FABP; Kamiya Biomedical, Seattle, WA), and N-terminal probrain natriuretic peptide (Neo Scientific, Cambridge, MA) were measured by ELISA in serum samples before infection and at the end of the experiment. Cytokine and chemokine analyses were performed using a validated Luminex multiplex assay for NHPs (30) .
Tissue Staining and Microscopy
Immunofluorescent and immunohistochemical (IHC) staining was performed with paraffin-embedded tissues as previously described (18 
Immunoblotting
Hearts were homogenized and processed as previously described (23) with protease (Sigma-Aldrich, St. Louis, MO) and phosphatase (Thermo Fisher Scientific, Waltham, MA) inhibitors.
Statistical Analysis
All data are presented as median with interquartile range (IQR) or mean with SD as appropriate. Paired nonparametric Wilcoxon signed-rank tests or two-tailed Student's t tests were used to compare data at different time points. All statistical calculations were performed using Prism 5 software (GraphPad Software, La Jolla, CA). Two-tailed P values less than 0.05 were considered statistically significant.
Results
Six NHPs with a median age of 11 (IQR, 10-19) years, which corresponds to middle-aged to elderly in humans, were included in the study. Details about each NHP, as well as an overview of the experiments done to develop the severe pneumococcal pneumonia model, were previously described (28) . Demographics and pneumonia severity are presented in Table E1 .
Noninvasive Cardiac Evaluation
ECG evaluation. During baseline evaluation, all animals were in sinus rhythm with normal PR, QT, and ST intervals ( Table 1 , Figure 1A ). P, T, and QRS waves resembled their normal morphology in humans ( Figure 1A ). At the end of the experiment, immediately before the animals were killed, ECG evaluation showed that all six NHPs had developed sinus tachycardia, diffuse repolarization abnormalities represented by diffuse ST segment changes, T-wave flattening, and prolongation of the corrected QT interval ( Figures 1B-1E , Table 1 ). Table 2 presents the individual interpretations of the 12-lead ECGs at baseline and at the end of the experiment. No other significant alterations were detected in the ECG tracings, even after the cohort was stratified by acute or convalescent pneumonia (Table E2) . Echocardiographic findings. A qualitative focused cardiac ultrasound examination was conducted at baseline and at the end of the experiment. Findings are summarized in Table E3 . Prior to infection, all six NHPs had normal focused cardiac ultrasound examinations. NHPs with acute pneumonia demonstrated hyperdynamic LV function, moderate tricuspid regurgitation, small pericardial effusions, and collapsed IVCs (central venous pressure ,5 mm Hg). NHPs with convalescent pneumonia developed increased LV relative wall thickness and some associated wall motion abnormalities (hypokinesis). (Figures 2A and 2C ). When we stratified the cohort by acute or convalescent pneumonia (i.e., with vs. without antibiotic treatment), troponin T and H-FABP remained higher at the end of the experiment in both cohorts, but the troponin T concentration was not statistically significant higher than it was at baseline ( Figures 2B and 2D ). In contrast, were assessed before infection, at Days 4-6 for the acute group, and at Days 9-14 for the convalescent group. Median (n = 6) serum concentrations of (A) troponin T, (C) H-FABP, and (E) NT-proBNP are shown before infection and at the end of the experiment (i.e., before animals were killed). To test whether antibiotic treatment could prevent cardiac damage, the cohort was stratified into nonhuman primates with acute pneumonia (i.e., without antibiotics; n = 6) and nonhuman primates with convalescent pneumonia (i.e., with antibiotics; n = 3). Serum levels of (B) troponin T, (D) H-FABP, and (F) NT-proBNP were assessed for each group before infection, at Days 4-6 for the acute group, and at Days (Figures 2E and 2F ).
Invasive Cardiac Evaluation
Detection of S. pneumoniae. We performed immunofluorescent staining of the different parts of the heart in all animals and confirmed the invasion of S. pneumoniae in the myocardium ( Figure 3A and 3B ). In NHPs with acute pneumonia, we observed clusters of pneumococci, suggesting that the bacteria were capable of replicating within the tissue. In contrast, in NHPs with convalescent pneumonia, only a few punctate points were observed, representing S. pneumoniae capsule debris ( Figure 3C ). Quantification of bacteria in heart homogenates confirmed that S. pneumoniae was present in NHPs with acute pneumonia, and none was detected in those with convalescent pneumonia or in uninfected control animals ( Figure E2 ). Histopathological findings. Tissue sections of the right or left ventricle and the interventricular septum showed similar lesions of a focal cardiac injury, primarily in perivascular sites, of varying extent and severity determined by hematoxylin and eosin staining ( Figure E3 ). Affected cardiac myocytes were enlarged, with a striking increase in eosinophilic staining, and were well demarcated from adjacent cardiac tissue ( Figures 4A-4C ). The damage of left ventricles and septum varied in terms of size and infiltration ( Figure E3 ). Varying degenerative and/or necrotic lesions were observed in the left ventricle and interventricular septum (Figures 4A-4C ). All animals had mild to severe myocyte fatty change and vacuolization, focal contraction bands, interstitial edema, focal myocytolysis, and scattered inflammatory cells ( Figures 4A and 4B) . We observed scattered myocytolysis in several myocytes ( Figures 4A and 4B ), but prominent nuclear pyknosis with extensive myocytolysis was apparent in several myocytes ( Figure 4C ). Two NHPs exhibited additional necrotic lesions defined by nuclear karyolysis and fragmentation, although one site had some clumped bacteria ( Figure 4C ).
Using TEM, we observed that infected NHPs consistently developed areas of vacuolization with focal contraction bands and interstitial edema in the left ventricle and septum ( Figures 4E and 4F) . Additionally, we identified several areas with focal myocytolysis and nuclear pyknosis that corresponded to extensive mitochondrial damage characterized by swollen and electron-lucent matrices ( Figure 4G ). Moreover, the mitochondrial cristae were degraded and disorganized and had decreased density. All these changes were evident in both the acute and convalescent pneumonia groups ( Figures  4E-4G) .
Cardiac inflammatory response. We observed high concentrations of cytokines and chemokines, including IL-6, tumor necrosis factor (TNF)-a, IL-8, IL-1b, IL-1Ra, and macrophage inflammatory protein 1a in homogenized hearts (left ventricle and interventricular septum) of all NHPs with acute pneumonia ( Figure 5 ). All three NHPs with convalescent pneumonia had lower heart concentrations of cytokines and chemokines than NHPs with acute pneumonia (Figures 5A-5F ). Significantly higher concentrations of IL-6, TNF-a, and IL-1b were seen in the left ventricle and interventricular septum of infected NHPs versus uninfected control animals ( Figures  5B, 5D , and 5E). IL-8 levels were higher in the interventricular septum ( Figure 5C ) of NHPs with convalescent pneumonia than in uninfected control animals.
Cardiomyocyte death. To test the role of necroptosis in cardiomyocyte death, we stained for RIP3 and pMLKL (necroptosis effector) in heart tissues from infected NHPs with acute and convalescent pneumonia and uninfected control animals using IHC staining ( Figure 6A ). An increased signal of both RIP3 and pMLKL was seen in stained tissues, suggesting that necroptosis was taking place throughout the myocardium. Increased levels of both RIP3 and pMLKL were confirmed by immunoblot analysis ( Figure 6B ). Additional staining of cardiac tissues with CardioTAC (R&D Systems, Minneapolis, MN) suggested apoptotic cells in the myocardium ( Figure E4 ). Briefly, CardioTAC labels DNA ends using terminal deoxynucleotidyl transferase. In addition, consistent with the presence of apoptotic cells in the myocardium, we observed an increase of apoptosis effector caspase 3 mainly in NHPs with acute pneumonia ( Figure E4 ). Collectively, these results suggest that S. pneumoniae induces programmed death pathways after it invades the myocardium.
Cardiac fibrosis. TGF-b in the heart stimulates myofibroblasts to produce collagen to replace dead cardiomyocytes (31, 32) . After S. pneumoniae had induced necroptosis in the heart, de novo collagen deposition was detected in the left ventricle and septum, as evidenced by picrosirius red staining ( Figure 7A ) and TEM ( Figure 7B ). Collagen deposition was seen 9-14 days after infection in convalescent animals. Additionally, using immunoblot analysis, we identified increased expression of pSMAD3, which stimulates collagen production in cardiac myofibroblasts (33) . Finally, to confirm that cardiac injury and collagen deposition were secondary to S. pneumoniae invasion, we explored the HIF-1a pathway that is activated by hypoxia (34) . Immunoblotting in homogenized hearts of NHPs confirmed that the HIF-1a pathway was downregulated in both the acute and convalescent pneumonia groups ( Figure E5 ).
Discussion
The results of our study provide novel evidence that, similarly to humans, NHPs with severe pneumococcal pneumonia develop signs of cardiac injury, including diffuse repolarization abnormalities, hyperdynamic LV function, and mild elevation of serum biomarkers (i.e., troponin T and H-FABP). Microscopic examination of heart tissues revealed that pneumococcus is capable of translocating into the myocardium and inducing cardiomyocytes by necroptosis and apoptosis. Moreover, we confirmed that heart invasion by S. pneumoniae causes severe cardiac injury and local proinflammatory responses independent of antibiotic treatment. We provide evidence that NHPs with convalescent pneumonia develop interstitial collagen deposition (i.e., scar formation) secondary to TGF-b pathway activation. Our findings are novel in that they provide translational data highlighting the etiological role of S. pneumoniae in causing MACE in patients with pneumonia. Further, collagen deposition in the myocardium may explain the increased long-term risk of MACE after an acute episode of pneumococcal pneumonia.
Up to 36% of patients hospitalized with CAP develop severe disease, which requires admission to the intensive care unit (35, 36) . Owing to the severe inflammatory response and mitochondrial dysfunction during severe pneumonia, at least 30% of patients develop LV dilation with a reduced ejection fraction, which usually takes 7-10 days to recover (i.e., sepsis-induced cardiomyopathy) (37, 38) . In addition, Corrales-Medina and colleagues showed recently in a cohort study that 10 to 30% of adults (without a clinical history of cardiac disease) admitted for CAP developed clinically relevant heart failure, arrhythmias, or acute coronary syndrome up to 10 years after hospitalization (6-8).
More commonly, up to 59% of patients admitted with sepsis develop a cardiac phenomenon called demand ischemia (i.e., mild troponin elevation and repolarization abnormalities in the absence of myocardial infarction or coronary disease) rather than sepsis-induced cardiomyopathy or MACE (39) (40) (41) . In our study, we found that all six previously healthy NHPs with pneumococcal pneumonia developed nonspecific cardiac changes that cannot be categorized as MACE but are consistent with what clinicians call demand ischemia. In contrast to human studies, in our present study, we were able to perform a detailed ex vivo examination of the NHP hearts, which revealed that S. pneumoniae can invade the heart and induce severe cardiac injury by killing cardiomyocytes through necroptosis and apoptosis. S. pneumoniae and its virulence factors (e.g., pneumolysin, cell wall) are cytotoxic and capable of inducing inflammation in cardiomyocytes (17, 19, 20) . Recently, our research group described the novel observation that the pneumococcus is capable of invading the myocardium and forming nonpurulent, bacteria-filled, microscopic lesions that were associated with cardiomyocyte death (apoptosis) and electrocardiographic abnormalities in mice with IPD (22) . In our experiments with severe pneumococcal pneumonia in NHPs, we proved that the pneumococcus is capable of invading the bloodstream and translocating the myocardium. In the hearts of NHPs, S. pneumoniae was observed in clusters, representing active replication, which did not form microlesions as previously described in mice (18) . This difference may be explained by the high bacterial load and longer infection times required to develop mature microlesions. Gilley and colleagues (18) recently described how cardiac invasion by pneumococcus occurs as soon as 12 hours after infection, but microlesion formation was dependent on bacterial load and time. Although similar findings have been reported in an IPD model that is not representative of pneumococcal pneumonia in humans, we used an NHP model of severe pneumonia that closely mimics the development and pathogenesis of human disease in that all the animals develop lowgrade bacteremia for a short period (28) .
Cardiomyocytes have been shown to die by apoptosis or necroptosis during Values are shown as medians and interquartile ranges. An unpaired nonparametric Mann-Whitney U test was used to analyze statistical differences among the groups. All comparisons were made against uninfected control animals. *P , 0.05; **P , 0.01; ***P , 0.001. ns = not significant.
injury or disease (24) (25) (26) . Apoptosis is an immunoquiescent form of cell death that requires the activity of cysteine proteases known as caspases (42) . It has been shown that mice lacking the death receptor Fas or mice treated with chemical inhibitors of caspases have reduced heart infarct sizes and fewer apoptosis-positive cells after ischemia-reperfusion injuries (43) . In contrast to apoptosis, necroptosis, or programmed necrosis, causes severe inflammation and tissue damage during disease (44) . Necroptosis is modulated by activation of RIP1, RIP3, and the effector molecule MLKL (25, 45) . Recently, Yin and colleagues showed that a nonspecific inhibitor of RIP1, necrostatin-1, could reduce infarct sizes after major ischemia or reperfusion injuries (46) . Using an NHP model, we showed that cardiomyocytes undergo RIP1-RIP3-MLKL-dependent necroptosis, and necroptosis inhibition with a selective drug has been shown to be protective against S. pneumoniae-induced cardiac damage, as reported by GonzalezJuarbe and colleagues (47) . This finding is significant because killing cardiomyocytes and inducing a proinflammatory response may contribute to the generation of MACE during pneumococcal pneumonia. Antibiotics have been shown to drastically reduce mortality resulting from pneumonia and other infectious diseases, and they are the cornerstone of CAP treatment (5) . Thus, to mimic the disease evolution of CAP in humans, we treated NHPs with ampicillin to explore whether antibiotic treatment could prevent the development of cardiac injury secondary to S. pneumoniae invasion. We found that antibiotic treatment did not protect NHPs from the development of necroptosis or cardiac injury and, more important, that NHPs treated with antibiotics had scar formation in the heart. These findings are consistent with our findings in mice rescued from IPD with antibiotics (17) and of other experiments in mice with ischemia-reperfusion injury (31) . This finding improves our understanding of MACE and the long-term mortality of patients with CAP. As described by Souders and colleagues, once cardiomyocytes die, heart tissue is replaced with myofibroblasts that produce an extracellular matrix that is rich in collagen and leads to scar formation (48) . Because S. pneumoniae is capable of inducing cardiac scar formation, and because cardiac scars are known to cause arrhythmias and heart failure, our findings might explain why MACE occur up to 10 years after the acute infection. MACE are the result of a complex host-pathogen interaction between underlying comorbidities, the infectious pathogen (9), systemic inflammation (49), endothelial dysfunction (50), a relative prothrombotic state (9) , increased cardiac oxygen demand, and low blood oxygen levels, which places considerable stress on the heart (9) . In this study, we show that pathogen-specific mechanisms of S. pneumoniae contribute to the development of cardiac damage during Values are shown as medians and interquartile ranges. Unpaired nonparametric Mann-Whitney U tests were used to analyze statistical differences among the groups. *P , 0.05; **P , 0.01; ns = not significant.
pneumococcal pneumonia that could lead to MACE. Our study has some important limitations. First, the experimental design was limited to a 2-week maximum duration, and the findings should not be interpreted as long-term clinical outcomes after surviving CAP. Second, the clinical evaluation was limited in capabilities to continuously assess oxygenation or hemodynamic parameters that could be associated with cardiac injury. However, at the end of the experiments, the NHPs were not hypotensive to a level requiring vasopressor support. Third, we did not specifically examine coronary arteries to identify thrombi or signs of myocardial infarction. However, we ruled out the clinical diagnosis of myocardial infarction according to the current guidelines of the American Heart Association (51). Finally, the sample size was limited to six NHPs with pneumococcal pneumonia owing to ethical considerations and high costs associated with the implantable continuous noninvasive cardiovascular monitoring systems and intensive veterinary medical care.
In summary, severe pneumococcal pneumonia led to the development of cardiac injury due to direct pathogen invasion, induction of cell death (necroptosis and apoptosis), and subsequent cardiac scar formation after antibiotic treatment in an NHP model. Further research is needed to develop strategies to mitigate the pathological mechanisms underlying cardiac injury secondary to pneumococcal invasion. n Author disclosures are available with the text of this article at www.atsjournals.org.
